First-in-Human Study of CLS003 ICVT in Subjects With Cutaneous Warts
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I/IIa study has an open-label, First-in-Human (FIH), single center design to
assess the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of multiple doses of
topically applied CLS003 in healthy subjects with cutaneous warts.